telatinib + capecitabine + cisplatin

This is a **combination therapy** consisting of **telatinib**, **capecitabine**, and **cisplatin**. Telatinib is an oral, small-molecule inhibitor of several receptor tyrosine kinases including vascular endothelial growth factor receptors (VEGFR-2 and VEGFR-3), platelet-derived growth factor receptor beta (PDGFR-β), and c-Kit. Capecitabine is an oral prodrug of 5-fluorouracil (5-FU), a pyrimidine antimetabolite, and cisplatin is a platinum-based DNA crosslinking agent. The combination has been evaluated in phase II trials for advanced gastric and gastroesophageal junction cancer as first-line therapy. The primary mechanism combines anti-angiogenic effects (telatinib), inhibition of DNA synthesis (capecitabine), and induction of DNA crosslinking/apoptosis (cisplatin). The combination has demonstrated a partial response rate exceeding 65% in preliminary results, which is higher than expected from capecitabine and cisplatin alone. Adverse events include gastrointestinal and vascular toxicities, typical for the component agents[2][4][5][6].